article thumbnail

Uber Health, Socially Determined Strike Partnership

MedCity News

Uber Health will then be able to offer its services to support those patients’ specific needs, whether it’s non-emergency medical transportation, same-day prescription delivery or grocery and over-the-counter item delivery.

article thumbnail

The financial toxicity of treating cancer

World of DTC Marketing

transportation), and indirect expenses (e.g., These cost estimates include cancer-attributable costs for medical services and oral prescription drugs. copayments and deductibles), nonmedical fees (e.g., lost work and income). National costs for cancer care were estimated to be $190.2 billion in 2015 and $208.9 population.

Insurance 273
article thumbnail

Uber Health Launches Grocery, Over-the-counter Delivery Service for Patients

MedCity News

They’ll be able to do this on the same platform they use to request non-emergency medical transportation and prescription delivery. Providers and payers will be able to use Uber Health to deliver healthy groceries and over-the-counter items to patients who need them.

article thumbnail

Enhancing Patient Healthcare with AI Chatbots

Referral MD

Patients can schedule appointments, request prescription refills, receive reminders , and access simple health information. Prescription refill reminders. Technology. It’s convenient for doctors’ offices and friends who cannot easily transport themselves to appointments. Medical advice for primary symptoms.

article thumbnail

Readjusting the Life Sciences Industry’s Approach to Improving Adherence

PM360

Addressing the issue of medication adherence begins before a patient even fills their first prescription. Part of this effort must include a consideration of social determinants of health (SDoH)—food, housing, transportation, access to care, etc.”. Eli Phillips, Jr.,

article thumbnail

Clarify Health Launches Real-World Evidence on Health Disparities

Clarify Health

With this launch, its life sciences products draw upon an expanded and extensive set of individual-level, de-identified SDoH factors, which are linked together with government and commercial claims, clinical, and prescription and dispensing data. Clarify has access to vast sources of clinically relevant consumer data for all Americans.

article thumbnail

FDA approves Ipsen’s Bylvay for cholestatic pruritus due to ALGS

Pharmaceutical Technology

Bylvay is a once-a-day, non-systemic ileal bile acid transport inhibitor (IBATi) that acts locally in the small intestine and has minimal systemic exposure. The therapy is being offered immediately through prescription for eligible ALGS patients. More than 90% of patients who received treatment with odevixibat were pruritus responders.